Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: A randomized, double-blind, comparative study

Journal of the Medical Association of Thailand

Volumn 95, Issue 10, 2012, Pages 1312-1316

  Tanglertsampan, Chuchai ^a  

^a Chandrakasem University   (Thailand)

Author keywords

Androgenetic alopecia; Male pattern hair loss; Topical finasteride; Topical minoxidil

Indexed keywords

FINASTERIDE; MINOXIDIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTACT DERMATITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GLOBAL PHOTOGRAPHIC ASSESSMENT; HAIR ANALYSIS; HUMAN; MALE; MALE TYPE ALOPECIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEXUAL DYSFUNCTION;

5-ALPHA REDUCTASE INHIBITORS; ADULT; ALOPECIA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; MINOXIDIL; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84869195236     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Olsen EA, Messenger AG, Shapiro J, Bergfeld WF, Hordinsky MK, Roberts JL, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005; 52: 301-11.
2. Ghanaat M. Types of hair loss and treatment options, including the novel low-level light therapy and its proposed mechanism. South Med J 2010; 103: 917-21.
3. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med 2011; 8: 1747-53.
4. Charuwichitratana S, Krisdapong P, Sumethiwit R, Tuchinda C. Randomized double-blind placebo controlled trial in the treatment of male androgenetic alopecia with 0.1% finasteride solution. Jpn J Dermatol 2003; 113: 881.
5. Sitticharoenchai P. Clinical evaluation of topical formulation of finasteride in male androgenetic alopecia [dissertation]. Bangkok: Chulalongkorn University; 2006.
6. Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol 2009; 75: 47-51.
7. Mazzarella F, Loconsole F, Cammisa A, Mastrolonardo M, Vena GA. Topical finasteride in the treatment of androgenetic alopecia: preliminary evaluations after a 16-month therapy course. J Dermatol Treat 1997; 8: 189-92.
8. Otberg N, Finner MA, Shapiro J. Androgenetic alopecia. Endocrinol Metab Clin N Am 2007; 36: 379-98.
9. Otberg N, Restrepo I, Shapiro J. Possibilities and limitations for reversal of age-related hair loss. In: Trueb RM, Tobin DJ, editors. Aging hair. Berlin: Springer Verlag; 2010: 193-213.
10. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998t; 39 (4 Pt 1): 578-89.
11. Shapiro J. Androgenetic alopecia: pathogenesis, clinical features and practical medical treatment. In: Shapiro J, editor. Hair loss: principles of diagnosis and management of alopecia. London: Martin Dunitz; 2002: 83-120.